Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2006; 52(6): 25-29


Influence of combined application of thesynthetic luteinizing hormone-releasing hormone agonist and non-steroidal antiandrogenon reproductive system of rate males

O.V.Sachinska, L.V.Chaikovska, A.G.Reznikov

    V.Komissarenko Institute of Endocrinology and Metabolism


Abstract

The influence of combined use of different doses of LGRH agonist (Surfagon) and non-steroidal antiandrogen Flutamide (Niftolid) on the structure and functional state of accessory sexual glands and hypophyseal-gonadal sys- tem of rate males had been studied. Optimal ratio of the drug doses for achieving the best antiprostatic effect has been determined. It was shown that combined use of above mentioned drugs resulted in the potentiation of antipros- tatic effects. A maximal effect was observed after 30 days of Surfagon administration in a dose of 50 mg/kg b.w. to- gether with flutamid in a dose of 10 mg/kg. b.w. Such a combination of drugs is recommended for clinical appro- bation as therapy for prostate cancer.

References

  1. Возианов А.Ф., Клименко И.А., Резников А.Г.. Эндокринная терапия рака предстательной железы. – К.: Наук. думка, 1999. – 280 с.
  2. Гончаров Н.Д. Острое влияние агонистов люлибе- рина на гипофизарную, тестикулярную и овариаль- ную функцию у обезьян //Пробл. эндокринологии. –1997. – 43, №2. – С.42–45.
  3. Нижерадзе И. А. Экспериментальные и клинические аспекты применения лютеинизирующего гормона- рилизинг-гормона и его аналогов // Там же. – 1996. –42, №5. – С. 40–42.
  4. Полякова Л.І., Чайковська Л.В., Резніков О.Г. Морфологічні зміни органів репродуктивної системи у щурів за умов сумісного застосування флутаміду і агоністів гонадоліберину у мінімальних дозах // Ендокринологія. – 2001. – 6, №1. – С.67–73.
  5. Шаткин А. Колориметрические методы определения ДНК, РНК и белка. – В кн.: Методы вирусологии и молекулярной биологии / Ред. К. Хабель, М.П. Зальцман. – М.: Мир, 1972. – С. 84–89.
  6. Baraghini G.F., Celani M.F., Zaidi et al. Problems as- sociated with the in vitro bioassay of serum luteinizing hormone (LH) on mouse Leydig cell preparations: methodological aspects //J. Endocrinol. Invest. –1984. –7, (suppl. 3). – P. 23–31.
  7. Chertin B., Spitz I.M., Lindenberg T. еt al. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer // J. Urol. – 2000. – 163, № 3. – P. 838–844.
  8. Labrie F. Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer // J. Androl. – 2004. – 25. – P. 305–313.
  9. 9. Naito S., Tachibana M., Deguchi T. еt al. Addition ofbicalutamide 80 mg to LHRH-agonist monotherapy in patients with advanced prostate cancer: Impact on quali- ty of life // J. Clin. Оncol. – 2004. – 22, № 14S. – P. 4703.
  10. 10. Pitteloud N., Hayes F.J., Dwyer A. et al. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism // J.Clin. Endocrinol. Metabol. – 2002. – 87. – P. 4128–4136.
  11. Trachtenberg J., Gittleman M., Steidle C. et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer // J. Urol. – 2002. – 167. – P. 1670–1674.

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2019.